CORRIGENDUM

A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model [Corrigendum]


The authors have advised due to an error that occurred inadvertently at the time of the resubmission process, Figure 11 on page 8121 is incorrect.

The immunohistochemical images were removed from the revised manuscript and the histograms were provided as both Figure 11 and 12. This error has also affected the Figure 11 and 12 citations in the text on pages 8118 and 8119.

Page 8118 and 8119, Hybrid Vaccine Treatment-Induced Increase in the Infiltration of CD4+ T, CD8+ T, and CD161+ NK Cells in Rat Glioma Tissue section, the paragraph should read as follows.

We subsequently assessed the infiltration (relative abundance) of CD4+ T, CD8+ T, and CD161+ NK cells in rat glioma tissue of the five treatment groups. The changes of CD4 + T, CD8 + T and CD161 + NK cells in glioma tissues of rats in the five treatment groups were evaluated by immunohistochemistry (Figure 11). Increased infiltration of CD4+ T cells was observed in the 9L + C6, thymosin, and 9L + C6 + thymosin treatment groups compared with the blank control group (Figure 12A; p < 0.05). No significant difference in the abundance of CD4+ T cells was observed in the tumor group. The abundance of CD8+ T cells was increased in the 9L + C6 and 9L + C6 + thymosin treatment groups compared with the blank control group (Figure 12B; p < 0.05). No significant change in CD8+ T-cell abundance was observed in the tumor and thymosin treatment groups (Figure 12B). Higher infiltration of CD161+ NK cells was observed in the 9L + C6 and 9L + C6 + thymosin treatment groups than in the blank control group (Figure 12C; p < 0.05). No significant change was observed in the infiltration of CD161+ NK cells in the tumor and thymosin treatment groups (Figure 12C).

Page 8121, Figure 11, the correct figure is as follows.

The authors wish to apologize for the error and advise it does not change the results of the paper.
Figure 11 Immunohistochemical images of the abundance of (A) CD4+ T cells, (B) CD8+ T cells, and (C) CD161+ natural killer (NK) cells in rat tumor tissues for the five treatment groups.